Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICARDIS HCT vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Treatment of hypertension, alone or in combination with other antihypertensive agents
Hypertension
One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Telmisartan: terminal half-life ≈24 hours, allowing once-daily dosing. Hydrochlorothiazide: 6-15 hours (mean 10 hours).
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Telmisartan is primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT1A8; it is not metabolized by CYP450 enzymes. Hydrochlorothiazide is not extensively metabolized; it is eliminated unchanged in the urine.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily biliary excretion (≈60%) and renal excretion (≈40%) as unchanged drug. Telmisartan: renal <1%, fecal >97%. Hydrochlorothiazide: renal >95% unchanged.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Telmisartan: >99.5% bound primarily to albumin and α1-acid glycoprotein. Hydrochlorothiazide: 40-68% bound to albumin.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Telmisartan: 500 L (≈7 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: 0.8-1.2 L/kg, confined to extracellular fluid.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Telmisartan: absolute oral bioavailability ≈42-58% (dose-dependent). Hydrochlorothiazide: oral bioavailability ≈65-75%.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Contraindicated if GFR <30 m L/min. No adjustment needed for GFR 30-89 m L/min. Monitor renal function.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh C). Caution and possible dose reduction in mild-to-moderate impairment; maximum 40 mg/12.5 mg daily.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Safety and efficacy not established in pediatric patients (<18 years).
Not established; avoid use in children.
No initial dose adjustment required; monitor blood pressure and renal function, especially with concurrent diuretic therapy.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None
None
Avoid use in pregnancy; can cause fetal harm when administered to a pregnant woman (discontinue as soon as possible when pregnancy is detected),May cause symptomatic hypotension in patients with volume or salt depletion,Monitor renal function; may cause acute renal failure, especially in patients with renal artery stenosis,Monitor serum electrolytes; risk of electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia) due to hydrochlorothiazide,May exacerbate or activate systemic lupus erythematosus,May cause acute angle-closure glaucoma (due to hydrochlorothiazide),May cause hypersensitivity reactions, including anaphylaxis and angioedema (telmisartan),Use with caution in patients with hepatic impairment (telmisartan),Use with caution in patients with diabetes or impaired renal function; may increase risk of renal impairment when used with NSAIDs or COX-2 inhibitors,Monitor for hyperuricemia and gout,May cause photosensitivity reactions
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to telmisartan, hydrochlorothiazide, or any component of the formulation,Anuria (due to hydrochlorothiazide),Concomitant use with aliskiren in patients with diabetes mellitus,Severe renal impairment (Cr Cl <30 m L/min),Severe hepatic impairment
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid high-potassium foods (bananas, oranges, tomatoes, spinach, salt substitutes) due to telmisartan's potassium-sparing effect. Hydrochlorothiazide may cause hypomagnesemia and hypokalemia; ensure adequate intake of magnesium-rich foods (nuts, whole grains) and potassium-rich foods (if not contraindicated). Avoid excessive alcohol intake which can increase hypotensive effect.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligohydramnios, skull ossification defects, hypotension, and anuria. Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Telmisartan is excreted in human milk in very low concentrations; M/P ratio unknown for telmisartan. Hydrochlorothiazide is excreted in breast milk; M/P ratio approximately 1.6. Avoid breastfeeding due to potential for adverse effects on the infant, including electrolyte disturbances and hypotension.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No dose adjustment data specific to pregnancy for Micardis HCT. Due to risk of fetal harm, use is contraindicated in pregnancy; discontinue as soon as pregnancy is detected. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may theoretically require dose adjustment, but no established guidelines.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
MICARDIS HCT (telmisartan/hydrochlorothiazide) is a fixed-dose combination for hypertension not controlled on monotherapy. Monitor renal function, electrolytes (especially potassium and sodium), and volume status. Avoid in severe renal impairment (Cr Cl <30 m L/min) and anuria. Assess for hypotension, particularly in volume-depleted patients. Use with caution in hepatic impairment, diabetes, and history of angioedema. May cause fetal harm in pregnancy; discontinue as soon as possible. Telmisartan is not dialyzable.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not skip doses or take double doses.,Notify your doctor immediately if you become pregnant or plan to become pregnant.,Avoid alcohol, NSAIDs, and salt substitutes containing potassium.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, confusion, or decreased urination.,This medication may increase blood sugar; monitor if you have diabetes.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICARDIS HCT vs ALDORIL 25, answered by our medical review team.
MICARDIS HCT is a Antihypertensive Combination (ARB + Thiazide Diuretic) that works by Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICARDIS HCT and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICARDIS HCT is: One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICARDIS HCT and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICARDIS HCT is classified as Category C. First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligoh. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.